Format

Send to

Choose Destination
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):387-397. doi: 10.1080/21691401.2017.1313267. Epub 2017 Apr 17.

RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies.

Author information

1
a Department of Pharmaceutics , JSS College of Pharmacy, Udhagamandalam (Jagadguru Sri Shivarathreeshwara University) , Tamil Nadu , India.
2
b Department of Pharmacology , JSS College of Pharmacy, Udhagamandalam (Jagadguru Sri Shivarathreeshwara University) , Tamil Nadu , India.
3
c Department of Pharmaceutics , GIET School of Pharmacy , Rajahmundry , Andhra Pradesh , India.

Abstract

In the present study, we have demonstrated receptor for advanced glycation endproducts (RAGE) as a target for delivery of drugs specifically to triple negative breast cancer cells. We have prepared solid lipid nanoparticle formulation of cytotoxic agent di-allyl-disulfide (DADS) to overcome its bioavailability issues. Then, we have surface modified DADS-loaded solid lipid nanoparticles (DADS-SLN) with RAGE antibody to achieve site-specific delivery of DADS to TNBC cells. We found a significant cellular internalization of RAGE surface modified DADS-SLN (DADS-RAGE-SLN) when compared to DADS-SLN. The cytotoxic effect of DADS was also significantly improved with DADS-RAGE-SLN by downregulating anti-apoptotic proteins and upregulating pro-apoptotic proteins as observed by western blot analysis. RAGE-targeted delivery of cytotoxic agents can be, therefore, a promising approach for improving antitumour activity and reducing off-target effects.

KEYWORDS:

Diallyl disulfide; apoptosis; breast cancer; receptor for advanced glycation endproducts; solid lipid nanoparticles

PMID:
28415882
DOI:
10.1080/21691401.2017.1313267
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center